(Q44171430)

30 November 2017

title

Economic and practical challenges to the formulation of vaccines against endemic infectious diseases such as malaria (English)

1 reference

30 November 2017

1 reference

1 reference

6

1 reference

30 November 2017

1

Magdalena Plebanski

1 reference

30 November 2017

Ester Lopez

2

1 reference

30 November 2017

Owen Proudfoot

series ordinal

3

1 reference

30 November 2017

Brian M Cooke

series ordinal

4

1 reference

30 November 2017

Mark von Itzstein

series ordinal

5

1 reference

30 November 2017

language of work or name

1 reference

1 September 2006

1 reference

30 November 2017

1 reference

30 November 2017

volume

40

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

77-85

1 reference

Childhood vaccine purchase costs in the public sector: past trends, future expectations

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

The economic impact of malaria in Africa: a critical review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

The past, present and future of childhood malaria mortality in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Economics and its contribution to the fight against malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Age-dependent enhancement of IFN-gamma responses to Plasmodium falciparum liver stage antigen-1 T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Pre-erythrocytic malaria vaccines: towards greater efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2006.05.021

10.1016/J.YMETH.2006.05.021

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference